Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus

Fig. 5

sSIGLEC-1 concentrations are increased in patients with active renal disease. a Box plots depict the distribution of sSIGLEC-1 concentrations in SLE patients with renal complications/nephritis, stratified by time since last episode of active nephritis. Information on duration of renal disease was available for 103 of the 156 patients with reported renal complications/nephritis in cohort 3. Mean sSIGLEC-1 levels are indicated for each population. P values were calculated using two-tailed Student’s t tests comparing sSIGLEC-1 concentrations between patients in each disease duration group and patients who never developed renal complications. b Correlation between sSIGLEC-1 levels and renal function, measured by estimated glomerular filtration rate (eGFR) in 280 SLE patients from cohort 3. **P < 0.01. eGFR estimated glomerular filtration rate, sSIGLEC-1 soluble sialic acid binding Ig-like lectin 1

Back to article page